Difference between revisions of "Prostate cancer with neuroendocrine differentiation"

From Libre Pathology
Jump to navigation Jump to search
(tweak)
 
(2 intermediate revisions by the same user not shown)
Line 2: Line 2:


'''Neuroendocrine carcinoma of the prostate''' redirect here.
'''Neuroendocrine carcinoma of the prostate''' redirect here.
==General==
*Treatment: platinum based therapy.


==Subclassification==
==Subclassification==
Line 13: Line 16:


==IHC==
==IHC==
*[[PSA]] typically negative in NE carcinoma.
*[[PSA]] typically negative in neuroendocrine carcinomas.


==See also==
==See also==
*[[Prostate cancer]].
*[[Prostate cancer]].
*[[Neuroendocrine carcinoma]].
*[[Neuroendocrine carcinoma]].
*[[Paneth cell-like change of the prostate gland]].


==References==
==References==

Latest revision as of 22:47, 19 March 2018

Prostate cancer with neuroendocrine differentiation is a rare group of prostate cancers that is hypothesized to evolve in the context androgen deprivation therapy.[1]

Neuroendocrine carcinoma of the prostate redirect here.

General

  • Treatment: platinum based therapy.

Subclassification

It is subclassified as per Epstein et al.:[1]

  • Usual prostate adenocarcinoma with neuroendocrine differentiation.
  • Adenocarcinoma with Paneth cell neuroendocrine differentiation.
  • Carcinoid tumour of the prostate.
  • Small cell carcinoma of the prostate gland.
  • Large cell neuroendocrine carcinoma of the prostate.
  • Mixed (small and/or large cell) neuroendocrine carcinoma-acinar adenocarcinoma.

IHC

  • PSA typically negative in neuroendocrine carcinomas.

See also

References

  1. 1.0 1.1 Epstein, JI.; Amin, MB.; Beltran, H.; Lotan, TL.; Mosquera, JM.; Reuter, VE.; Robinson, BD.; Troncoso, P. et al. (Jun 2014). "Proposed morphologic classification of prostate cancer with neuroendocrine differentiation.". Am J Surg Pathol 38 (6): 756-67. doi:10.1097/PAS.0000000000000208. PMID 24705311.